290 related articles for article (PubMed ID: 19549896)
1. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.
Racanelli AC; Rothbart SB; Heyer CL; Moran RG
Cancer Res; 2009 Jul; 69(13):5467-74. PubMed ID: 19549896
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
Rothbart SB; Racanelli AC; Moran RG
Cancer Res; 2010 Dec; 70(24):10299-309. PubMed ID: 21159649
[TBL] [Abstract][Full Text] [Related]
3. AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells.
Agarwal S; Bell CM; Rothbart SB; Moran RG
J Biol Chem; 2015 Nov; 290(46):27473-86. PubMed ID: 26391395
[TBL] [Abstract][Full Text] [Related]
4. [Pemetrexed: from preclinic to clinic].
Lansiaux A; Lokiec F
Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed disodium.
Gibbs D; Jackman A
Nat Rev Drug Discov; 2005 May; Suppl():S16-7. PubMed ID: 15962527
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
Adjei AA
Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed and its emerging role in the treatment of thoracic malignancies.
Scagliotti GV; Novello S
Expert Opin Investig Drugs; 2003 May; 12(5):853-63. PubMed ID: 12720495
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.
Hanauske AR; Chen V; Paoletti P; Niyikiza C
Oncologist; 2001; 6(4):363-73. PubMed ID: 11524555
[TBL] [Abstract][Full Text] [Related]
11. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
Scagliotti GV; Selvaggi G
Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed disodium, a novel antifolate with multiple targets.
Curtin NJ; Hughes AN
Lancet Oncol; 2001 May; 2(5):298-306. PubMed ID: 11905785
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed: an active new agent for breast cancer.
O'Shaughnessy JA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):57-62. PubMed ID: 12571813
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed (Alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma.
Manegold C
Semin Oncol; 2003 Aug; 30(4 Suppl 10):32-6. PubMed ID: 12917819
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.
Adjei AA
Ann Oncol; 2000 Oct; 11(10):1335-41. PubMed ID: 11106124
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of reduced folate carrier-mediated folate/antifolate transport through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphate.
Visentin M; Zhao R; Goldman ID
Mol Pharmacol; 2012 Aug; 82(2):209-16. PubMed ID: 22554803
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed disodium for the treatment of NSCLC: an update.
Hsu JY; Wakelee H
Drugs Today (Barc); 2008 Sep; 44(9):669-78. PubMed ID: 19137122
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed: current development and future directions in thoracic cancers.
Manegold C
Suppl Tumori; 2002; 1(4):S11-2. PubMed ID: 12415805
[No Abstract] [Full Text] [Related]
19. Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
Scagliotti GV
Lung Cancer; 2005 Oct; 50 Suppl 1():S18-9. PubMed ID: 16291426
[TBL] [Abstract][Full Text] [Related]
20. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
